Power Calculations for Clinical Trials in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The Alzheimer research community is actively pursuing novel biomarker and other biologic measures to characterize disease progression or to use as outcome measures in clinical trials. One product of these efforts has been a large literature reporting power calculations and estimates of sample size for planning future clinical trials and cohort studies with longitudinal rate of change outcome measures. Sample size estimates reported in this literature vary greatly depending on a variety of factors, including the statistical methods and model assumptions used in their calculation. We review this literature and suggest standards for reporting power calculation results. Regardless of the statistical methods used, studies consistently find that volumetric neuroimaging measures of regions of interest, such as hippocampal volume, outperform global cognitive scales traditionally used in clinical treatment trials in terms of the number of subjects required to detect a fixed percentage slowing of the rate of change observed in demented and cognitively impaired populations. However, statistical methods, model assumptions, and parameter estimates used in power calculations are often not reported in sufficient detail to be of maximum utility. We review the factors that influence sample size estimates, and discuss outstanding issues relevant to planning longitudinal studies of Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827 · cited 1×
“Image processing can be based on manual tracings [33], semi-automated methods and fully automated methods (e.”
. Caution regarding the use of pilot studies to guide power calculations for study proposals.
Kraemer, H. C., Mintz, J., Noda, A., Tinklenberg, J., & Yesavage, J. A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.484 · Cited by 702 · cited 1×
“under consideration [28].”
Subregional neuroanatomical change as a biomarker for Alzheimer's disease
Holland, D., Brewer, J. B., Hagler, D. J., Fennema-Notestine, C., Dale, A. M., Initiative, T. A. D. N., Weiner, M., Thal, L., Petersen, R., Jack, C. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906053106 · Cited by 210 · cited 1×
“Several of the papers reviewed here reported sample sizes using formula (3), either in lieu of [19], or in addition to [11, 17], formula (2).”
Hua, X., Lee, S., Yanovsky, I., Leow, A. D., Chou, Y.-Y., Ho, A. J., Gutman, B., Toga, A. W., Jack, C. R., Bernstein, M. A., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.07.011 · Cited by 145
Stein, J. L., Hua, X., Morra, J. H., Lee, S., Hibar, D. P., Ho, A. J., Leow, A. D., Toga, A. W., Sul, J. H., Kang, H. M., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.068 · Cited by 145 · cited 2×
“, detection of correlations, differences between dementia types, or the presence of atrophy) using a non-analytic sample-reduction method in which subjects were randomly discarded from the pilot data set until it was no longer possible to reject the hypotheses in question [22–27].”
BackgroundMethodChou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117
Cited by
Mulder, E. R., de Jong, R. A., Knol, D. L., van Schijndel, R. A., Cover, K. S., Visser, P. J., Barkhof, F., & Vrenken, H. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.01.058 · Cited by 122
“As may be expected, segmentation failures were slightly more frequent in AD (7 out of 20 patients had failures) than in MCI (7 out of 40 patients had failures) or healthy controls (4 out of 20 subjects had failures).”
InfluentialMicrobial involvement in Alzheimer disease development and progression
Bulgart, H. R., Neczypor, E. W., Wold, L. E., & Mackos, A. R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00378-4 · Cited by 116
Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials
Dodge, H. H., Zhu, J., Mattek, N. C., Austin, D., Kornfeld, J., & Kaye, J. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138095 · Cited by 99
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Horr, T., Messinger-Rapport, B., & Pillai, J. A. (2015) · The Journal of nutrition, health and aging · doi:10.1007/s12603-014-0565-6 · Cited by 67
“Calculations in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data set using these measures have consistently estimated sample sizes of over 100 MCI subjects per arm of the study, although reported sample size estimates for each measure are more often larger and widely divergent (53-58).”
Metadata
- Authors
- Ard, M. C., & Edland, S. D.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-10-04
- Volume
- 26
- Issue
- s3
- Pages
- 369-377
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1561315863
- Cited by
- 74
- References
- 7
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Power Calculations for Clinical Trials in Alzheimer's Disease. https://app.cochat.ai/papers/10.3233/jad-2011-0062
- The paper
- Ard, M. C., & Edland, S. D. (2011). Power Calculations for Clinical Trials in Alzheimer's Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2011-0062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.